Skip to Content

SSY Group Ltd LJUIF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

SSY Group Ltd is a specialty and generic drug manufacturing company. The company reports multiple segments including pharmaceutical products, medical materials, services income, raw materials, and by-products and rental income. The company derives a vast majority of its revenue principally from the sale of finished medicines to hospitals and distributors. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials. Over 95% of SSY Group's revenue and operating profits are derived from China.

Contact
Central Plaza, 18 Harbour Road, Rooms 4902-03, 49th Floor
Hong Kong, Cayman Islands
T +852 26880869
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Fiscal Year End Dec 31, 2020
Stock Type
Employees 4,700